市場調査レポート
商品コード
1399412

世界の臍帯血・組織バンク産業の分析:市場規模、セグメンテーション、予測 (2024年)

Global Cord Blood and Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024

出版日: | 発行: BioInformant | ページ情報: 英文 295 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
世界の臍帯血・組織バンク産業の分析:市場規模、セグメンテーション、予測 (2024年)
出版日: 2024年03月01日
発行: BioInformant
ページ情報: 英文 295 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

エグゼクティブサマリー

臍帯血由来造血幹細胞を用いた最初の移植が行われたのは1988年10月のことで、その年以来、臍帯血由来の造血幹細胞および前駆細胞の研究は目覚ましい成果をあげてきました。現在までに、血液疾患、代謝疾患、免疫疾患、腫瘍性疾患、神経疾患などを含む疾患の治療のために、小児から成人まで、世界のさまざまな地域で4万件を超える臍帯血移植 (UCBT) が行われてきました。現在、公的臍帯血バンクに保管されている臍帯血は80万個を超え、民間バンクに保管されている臍帯血・組織単位は全世界で675万個を超えています。

臍帯血保存は1990年代初頭に商業サービスとして登場したが、臍帯組織保存が商業サービスとして登場したのは、2008年に台湾のHealthBanks Biotech Company Ltd.が世界初のサービスを開始してからです。その後、香港のHealthBabyが2009年にサービスを開始しました。香港を拠点とするCryolifeも2009年にサービスを開始しました。米国では、2010年7月にCord Blood Registry (CBR) が民間企業として初めて臍帯組織保管サービスを開始しました。現在では、米国のほぼすべての臍帯血バンクと、世界の臍帯血バンクの約3分の1が臍帯組織保管サービスを提供しています。

治療上と財務上の理由から、臍帯血業界では近年、記録的なレベルの合併・買収 (M&A) が行われています。現在、世界の臍帯血市場の大部分は、世界最大の臍帯血バンク事業者10社によって支配されています。大手市場の競合企業には、Global Cord Blood Corporation (GCBC)、Cord Blood Registry (CooperSurgical所有)、ViaCord、Cryo-Cell International、Cordlife Group、VCANBIO Cell &Gene Engineering Corporation、Lifecell International、Cryoholdco、Medipostなどがあります。

現在、臍帯血・臍帯組織市場にはいくつかの市場セグメントがあります。第一に、保存 (凍結保存) 市場です。この市場セグメントは、臍帯血の採取と処理、および長期保存契約から収益を生み出しています。近年、複数の投資会社が臍帯血バンクの株式を取得し、臍帯血バンク市場に参入しています。第二に、白血病から鎌状赤血球症に至るまで、さまざまな疾患の治療のための移植医療における臍帯血の利用も、堅調な市場を形成しています。現在までに、4万件以上の臍帯血移植 (UCBT) が実施され、80種類以上の病状が臍帯血の造血幹細胞を用いた治療として承認されています。

第三に、再生医療への応用において、臍帯血や組織の利用を模索する企業が増えています。2000年代半ば、科学者たちは後天性の神経学的適応症における臍帯血の研究を開始しました。脳性麻痺、自閉症スペクトラム障害、後天性難聴などの小児患者を登録したパイロット試験や臨床試験により、治療目的で最小限の操作で臍帯血を投与することの安全性が実証されました。別の例では、RheinCell Therapeutics (現在はCatalentが所有) が、ヒトグレードの細胞療法の製造に使用する臍帯血由来iPSCを製造するためのGMP認証を取得しました。ClinicalTrials.govによると、1,200件以上の臨床試験が臍帯血幹細胞や前駆細胞の使用を評価しています。これらの研究では、操作されていない全臍帯血 (全有核細胞/TNC)、単核細胞 (MNC)、または臍帯血由来の間葉系幹細胞 (MSC) が使用されています。2023年4月、米国FDAは世界初の拡大臍帯血細胞療法 (Omisirge) も承認しました。オミシルジは、がん患者の白血球の回復を早める同種臍帯血細胞療法として、Gamida Cellが開発しています。

最後に、細胞・組織・試薬・キットを含むがこれらに限定されない、臍帯血や組織由来の研究用供給製品の市場が拡大しています。研究領域では、臍帯血製品 (新鮮および凍結保存) は、Lonza、STEMCELL Technologies、AllCells、その他数十社を含む、様々な大手企業によって提供されています。

当レポートでは、世界の臍帯血・臍帯組織バンク業界の最新動向と将来展望について分析し、技術の概略や市場の基本構造、コスト・収益モデルと今後の見通し、全体的な市場規模の動向見通し (2030年まで)、地域別・適応症別・バンクの種類別 (公共/民間) などの詳細動向、主要企業のプロファイルなどを調査しております。

目次

第1章 分析概要

第2章 臍帯血バンク:概要

  • 臍帯血試料の成分
  • 臍帯血バンク
    • 公共臍帯血バンク
    • 民間臍帯血バンク
    • ハイブリッド臍帯血バンク
    • クロスオーバー臍帯血バンク
    • コミュニティ臍帯血バンク
  • 米国における公共・民間・ハイブリッド臍帯血バンクの割合

第3章 臍帯血バンクの認定

  • AABB (American Association of Blood Banks)
    • AABB認定の段階と期待
  • FACT (Foundation for the Accreditation of Cellular Therapy)
    • FACTの基準
    • FACTの認定プロセス
  • 臍帯血バンクのFDAへの登録
    • FDAの臍帯血向けBLS (生物製剤ライセンス申請)
    • 臍帯血のIND (新薬調査)
  • 英国:HTA (Human Tissue Authority)
  • オーストラリア:TGA (Therapeutic Goods Act)
  • International NetCord Foundation

第4章 臍帯血・臍帯組織・胎盤の情勢

  • 臍帯血幹細胞の特許
    • 臍帯血特許の法的地位
    • 臍帯血特許の出願件数:年別
    • 臍帯血特許の出願件数:管轄区域別
    • 臍帯血特許の出願人:上位10名
    • 臍帯血特許の発明者:上位10名
    • 臍帯血特許の所有者:上位20社
  • 臍帯血由来MSC (間葉系幹細胞) に関する特許
    • 臍帯血由来MSC特許の法的地位
    • 臍帯血由来MSC特許の出願件数:年別
    • 臍帯血由来MSC特許の出願件数:管轄区域別
    • 臍帯血由来MSC特許の出願人:上位10名
    • 臍帯血由来MSC特許の発明者:上位10名
    • 臍帯血由来MSC特許の所有者:上位20社
  • 臍帯組織に関する特許
    • 臍帯組織特許の法的地位
    • 臍帯組織特許の出願件数:年別
    • 臍帯組織特許の出願件数:管轄区域別
    • 臍帯組織特許の出願人:上位10名
    • 臍帯組織特許の発明者:上位10名
    • 臍帯組織特許の所有者:上位20社
  • 胎盤に関する特許
    • 胎盤ベース特許の主な出願人
    • 胎盤特許の出願件数 (2000年~2022年)
    • 胎盤特許の管轄区域:上位10地域
    • 胎盤特許の発明者:上位10名
    • 胎盤特許の所有者:上位20社
    • 胎盤特許の法的地位
  • 臍帯血増殖に関する特許
    • 臍帯血 (CB) 増殖の特許出願件数:年別
    • CB増殖特許の管轄区域:上位10地域
    • 臍帯血増殖特許の法的地位
    • 臍帯血増殖特許の発明者:上位10名
    • 臍帯血増殖特許の所有者:上位20社

第5章 臍帯血の研究刊行物

  • 臍帯血に関する論文の件数
  • 臍帯組織に関する科学刊行物
  • 胎盤組織に関する科学刊行物
  • 臍帯血 (UCB) 細胞増殖に関する科学刊行物

第6章 臨床試験:臍帯血、臍帯組織、胎盤、CB増殖

  • 臍帯血幹細胞に関する臨床試験
    • 臍帯血幹細胞を使用した臨床試験の件数:地域別
    • 臍帯血の臨床試験の件数:研究の種類別
    • 臨床試験の件数:研究段階別
    • 臨床試験の件数:資金提供者別
    • 現在募集中の臍帯血臨床試験が対象とする疾患
    • 臍帯血臨床試験に参加する企業
  • 臍帯組織を用いた臨床試験
    • 臍帯組織を使用した臨床試験の件数:地域別
    • 臍帯組織の臨床試験の件数:研究段階別
    • 臍帯組織の臨床試験の件数:資金提供者の種類別
    • 臍帯組織の臨床試験における営利団体
  • 胎盤組織幹細胞を用いた臨床試験
    • 胎盤組織の臨床試験の件数:研究段階別
  • 増殖臍帯血の臨床試験
    • 増殖臍帯血細胞を用いた臨床試験の主な参加者

第7章 臍帯血処理技術:概要

  • 臍帯血幹細胞の分離プロセス
    • PrepaCyte CB
    • Hetastarch (HES)
    • AutoXpress (AXP)
    • SEPAX
    • 血漿除去法 (MaxCellプロセス)
    • 密度勾配法
  • 異なる処理方法のメリットの比較
    • 初期段階のHSC回収:技術別
    • 中期段階のHSC (CD34+/CD133+) のCBからの回収:技術別
    • 後期段階の臍帯血からのHSCの回収:技術別
    • HSC (CD45+) の回収
  • 好中球の生着までの日数:技術別
  • 臍帯血処理に使用される抗凝固剤
    • 抗凝固剤の種類と細胞回収量
  • 細胞回収率:試料サイズ別
  • TNCの生存率:輸送所用時間別・抗凝固剤の種類別
  • 臍帯血細胞の凍結保存
    • 理想的な凍結防止剤
  • 臍帯組織 (UCT) のバイオプロセス
  • 臍帯血増殖技術
    • Notch Ligand Delta 1
    • MSCとの共培養
    • 銅キレート化
    • ニコチンアミド
    • StemRegenin 1 (SR1)
    • UM171
    • ホーミングの強化
    • Prostaglandin E2
    • 補体3a (C3a)
    • フコシル化

第8章 世界中で利用可能な臍帯血ユニット:概要

  • 世界中で利用可能な同種CBUドナーとCBUの数
  • 世界の無関係なCBドナーおよびCBUのHLAタイピング (2021年)
  • 無関係なBM、PB、CBの造血幹細胞ユニット:世界各国への出荷
  • 臍帯血HSCの世界規模の交換

第9章 臍帯血移植の適応

  • 臍帯血幹細胞の有益な特性
    • UCBCの造血特性
    • UCBCの免疫特性
    • UCBTレシピエントにおけるHLA不一致の影響
  • UCB移植の悪性適応症
  • UCB移植によって治療される非悪性疾患
  • 再生医療としてUCBを使用して研究されている疾患

第10章 臍帯血:移植薬として

  • CB、BM、PB幹細胞移植数の比較
  • 臍帯血幹細胞の移植件数:地域別 (1999年~2021年)
    • 米国における造血幹細胞移植 (HSCT) の適応
    • 米国における民族的背景と臍帯血HLAの一致
    • 臍帯血移植の費用
    • HCT後1年後の合併症

第11章 再生医療における臍帯血幹細胞

  • 自閉症
  • 脳性麻痺
  • アルツハイマー病
  • 糖尿病
  • 心疾患
  • 多発性硬化症
  • 脳卒中

第12章 市場分析

  • 臍帯血バンクサービス市場
    • 臍帯血バンクサービス市場の収益シェア:地域別
    • 臍帯血バンクサービス市場:公共 vs 民間
    • 世界の臍帯血・臍帯組織サービスの市場シェア
  • 世界の臍帯血・臍帯組織の治療用途の市場
    • 移植用CB・再生医療用CBの市場シェア
    • 臍帯血・臍帯組織の市場シェア:適応症別
  • 世界の臍帯組織 (UCT) 市場

第13章 主要な臍帯血バンク・関連組織のプロファイル

  • AllCells
  • AlphaCord
  • Americord Registry, Inc.
  • Angiocrine Bioscience
  • Anja Health Personalized Cord Blood Banking
  • Baylx, Inc.
  • Be The Match
  • Biocell Center
  • BioEden
  • BioIntegrate, LLC
  • Bloodworks Northwest
  • California Umbilical Cord Collection Program
  • Carolinas Cord Blood Bank (CCBB)
  • Celaid Therapeutics
  • Celebration Stem Cell Centre (CSCC)
  • Cell Care
  • Cellenkos, Inc.
  • Cells4Life Group LLP
  • CellSave Arabia
  • Celularity, Inc.
  • Center for International Blood and Marrow Transplant Research (CIBMTR)
  • CHOC Blood Bank
  • Cleveland Cord Blood Center
  • ClinImmune Cell and Gene Therapy
  • Cord Blood Bank of Arkansas (CBBA)
  • Cord Blood Center Group
  • Cord Blood Registry (CBR)
  • Cord for Life
  • CordLife Group, Ltd.
  • CordVida
  • Crioestaminal
  • Cryo-Cell International, Inc.
  • CryoCyte, LLC
  • CryoHoldco LATAM
  • Cryopoint
  • Cryoviva Biotech Pvt., Ltd.
  • DKMS gGMBH
  • Duke University School of Medicine
  • European Society for Blood and Bone Marrow Transplantation (EBMT)
  • Ever Supreme Bio Technology, Co., Ltd.
  • ExCellThera
  • FamiCord Group
  • Fate Therapeutics, Inc.
  • Future Health
  • Gamida Cell
  • GeneCell
  • Global Cord Blood Corporation (GCBC)
  • Glycostem Therapeutics
  • Hawaii Cord Blood Bank
  • HealthBaby
  • HealthBanksUSA
  • HEMAFUND
  • Hemogenyx Pharmaceuticals
  • IMMUNIQUE
  • Insception LifeBank
  • JP McCarthy Cord Stem Cell Bank
  • Kangstem Biotech, Co., Ltd.
  • LifebankUSA
  • LifeCell International Pvt. Ltd.
  • Life Line Stem Cell
  • LifeSouth Cord Blood Bank
  • Magenta Therapeutics
  • Maze Cord Blood
  • Medipost, Co., Ltd.
  • Mesoblast, Ltd.
  • MD Anderson Cord Blood Bank
  • Mesoblast, Ltd.
  • MiracleCord, Inc.
  • Mononuclear Therapeutics, Ltd.
  • New England Cord Blood Bank, Inc.
  • New York Blood Center
  • OrganaBio
  • PacifiCord
  • Plasticell Ltd.
  • ReeLabs Pvt. Ltd.
  • Restem, LLC
  • San Diego Cord Blood Bank
  • Saneron CCEL Therapeutics, Inc.
  • SmartCells
  • SSM Cardinal Glennon Children's Medical Center
  • Stembanc, Inc.
  • Stem Cell Cryobank, Inc.
  • StemCyte, Inc.
  • Throne Biotechnologies, Inc.
  • Transcell Biolife
  • Upstate Cord Blood Bank
  • ViaCord
  • Versity, Inc.
  • Vita 34 AG
  • Vitalant Clinical Services
  • World Marrow Donor Association (WMDA)
  • Worldwide Network for Blood & Marrow Transplantation (WBMT)

図の一覧

表の一覧

目次

Executive Summary

The first transplant using cord blood-derived hematopoietic stem cells was performed in October 1988, and since that year, remarkable achievements have been made regarding research into umbilical cord blood-derived hematopoietic and progenitor cells. To date, more than 40,000 UCB transplants (UCBTs) have been performed across different geographies of the world, in both children and adults, to treat diseases that include hematologic, metabolic, immunologic, neoplastic, and neurologic disorders. There are now over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.

Although cord blood storage emerged as a commercial service in the early 1990s, cord tissue storage did not emerge as a commercial service until 2008, when a Taiwanese company, HealthBanks Biotech Company Ltd., began offering the service making it the first company worldwide to do so. HealthBaby, a Hong Kong based company subsequently launched the service in 2009. Hong Kong-based Cryolife, added the service in 2009 as well. Within the U.S., Cord Blood Registry (CBR) was the first private company to begin offering cord tissue storage in July of 2010. Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.

For placental banking, LifebankUSA initiated the service in the U.S. when it launched placental blood storage in 2006 and placental tissue storage in 2011. In September 2017, Americord Registry became the second U.S. cord blood bank to provide placental tissue banking. Internationally, a few dozen cord blood banks offer placental blood and tissue storage services. Some cord blood banks have also diversified into the storage of other types of stem cell derivatives, such as dental pulp stem cells. For example, DentCell is a dental pulp stem cell bank controlled by Cryoholdco, the largest cord blood banking consolidator in Latin America. A small number of cord blood banks have also expanded into adipose-derived stem cell storage.

For both therapeutic and financial reasons, the cord blood industry has been witnessing record levels of merger and acquisition (M&A) activity in recent years. The vast majority of the global cord blood market is now controlled by the world's 10 largest cord blood banking operators. Large market competitors include Global Cord Blood Corporation (GCBC), Cord Blood Registry (owned by CooperSurgical), ViaCord, Cryo-Cell International, Cordlife Group, VCANBIO Cell & Gene Engineering Corporation, Lifecell International, Cryoholdco, and Medipost.

This is incredible, given that the cord blood industry grew exponentially in the early 2000s but has consolidated dramatically since that time. Industry consolidation has been particularly compelling within the U.S, Europe, Asia, and Latin America, with:

  • PBKM FamiCord consolidating the majority of the European market through aggressive M&A activity (and Cryo-Save AG's 2019 bankruptcy).
  • CooperSurgical aggregating reproductive, newborn stem cell, and genetic services within the U.S., for a total of at least 1.1 million units under management.
  • Cryoholdco aggregating stem cell banking assets across Latin America, including at least four assets in Mexico, two in Columbia, two in Brazil, and one in Peru, for an estimated 300,000 units.
  • Sanpower Group dominating the Asian market. Headquartered in Nanjing, Sanpower owns Global Cord Blood Corporation and other assets across Southeast Asia, controlling more than 1.2 million units.

Another key market is India, which has surged to an astounding population of 1.4 billion. Recent population growth has placed it head-to-head with China as the world's most populous country. China also has a population of 1.4 billion. This means that an incredible one-third (36%) of the world's 7.8 billion people now live within these two countries. Within India, LifeCell International is the market leader, with over 320,000 stem cell units under storage.

In addition to market consolidation, there have been substantial advances made with perinatal tissue applications-including umbilical cord blood, umbilical cord tissue, placental blood and tissue, and amniotic fluid-causing storage services for these biomaterials to proliferate. A surging number of cord blood banks are also expanding their service offerings to include:

  • Reproductive and assisted fertility services
  • Pre- and post-natal genetic testing services
  • Cell therapy product development

Several market segments now compose the umbilical cord blood and tissue market. First, there is the storage (cryopreservation) market. This market segment generates revenue from cord blood collection and processing, as well as long-term storage contracts. In recent years, several investment firms have entered the cord blood banking market by acquiring ownership stakes in cord blood banks. Second, there is also a robust market for the use of cord blood within transplantation medicine for the treatment of diseases ranging from leukemia to sickle cell disease. To date, more than 40,000 UCB transplants (UCBTs) have been performed and over 80 medical conditions are approved to be treated using HSCs from cord blood.

Third, a growing number of companies are exploring the use of cord blood and tissue within regenerative medicine applications. In the mid-2000s, scientists started investigating cord blood in acquired neurological indications. Pilot and clinical trials enrolling pediatric patients with disorders such as cerebral palsy, autism spectrum disorder, and acquired hearing loss have demonstrated the safety of administering minimally manipulated cord blood for therapeutic purposes. In another example, RheinCell Therapeutics (presently owned by Catalent) achieved GMP certification to manufacture cord blood-derived iPSCs for use in the production of human-grade cell therapies. According to ClinicalTrials.gov, over 1,200 clinical trials are evaluating the use of cord blood stem and progenitor cells. These studies use unmanipulated whole cord blood (total nucleated cells/TNC), mononuclear cells (MNC), or cord blood-derived mesenchymal stem cells (MSCs). In April 2023, the U.S. FDA also approved the world's first-ever expanded cord blood cell therapy (Omisirge). Omisirge is being developed by Gamida Cell as an allogeneic cord blood cell therapy to speed up the recovery of white blood cells in cancer patients.

Finally, there is a growing market for cord blood and tissue-derived research supply products, including but not limited to cells, tissues, reagents, and kits. Within the research realm, cord blood products (fresh and cryopreserved) are now being offered by a diverse range of major market leaders, including Lonza, STEMCELL Technologies, AllCells, and dozens of others.

Overall, this report presents findings on the following topics:

  • 1. Number of cord blood and tissue units cryopreserved in public and private cord blood banks worldwide
  • 2. Number of hematopoietic stem cell transplants (HSCTs) performed globally using cord blood cells
  • 3. Utilization of cord blood cells in regenerative medicine clinical trials
  • 4. The decline of the utilization of cord blood cells in HSCT since 2005
  • 5. Emerging technologies that will influence the financial sustainability of public cord blood banks
  • 6. The future scope for companion products derived from cord blood
  • 7. The changing landscape of the cord blood and tissue banking market
  • 8. Expansion and extension of services by cord blood banks
  • 9. Types of cord blood banks
  • 10. Economic model of public cord blood banks
  • 11. Cost analysis for public cord blood banks
  • 12. Economic model of private cord blood banks
  • 13. Cost analysis for private cord blood banks
  • 14. Profit margins for private cord blood banks
  • 15. Pricing for processing and storage in private banks
  • 16. Rate per cord blood unit in the U.S. and Europe
  • 17. Indications for the use of cord blood-derived HSCs within transplantation medicine
  • 18. Diseases targeted by cord blood-derived MSCs in regenerative medicine
  • 19. Cord blood processing technologies
  • 20. Number of clinical trials, number of published scientific papers, and amount of NIH funding for cord blood research
  • 21. Number and types of patents for cord blood, cord tissue, and placental products
  • 22. Transplantation data from different cord blood registries

Key questions answered within this market report are:

  • 1. What are the strategies being considered to improve the financial stability of public cord blood banks?
  • 2. What are the companion products being developed from cord blood and tissue?
  • 3. How much is spent to process and store a unit of cord blood?
  • 4. How much does a unit of cryopreserved cord blood unit fetch on release?
  • 5. Why do most public cord blood banks incur a loss?
  • 6. What is the net profit margin for a private cord blood bank?
  • 7. What are the prices for processing and storage of cord blood in private cord blood banks?
  • 8. What are the rates per cord blood unit in the U.S. and Europe?
  • 9. What are the revenues from cord blood sales for major cord blood banks?
  • 10. What are the different accreditation systems for cord blood and tissue banks?
  • 11. What are the comparative merits of the various cord blood processing technologies?
  • 12. What is to be done to increase the rate of utilization of cord blood cells in transplantation medicine?
  • 13. Which TNC counts are preferred for transplantation?
  • 14. What is the number of registered clinical trials using cord blood and cord tissue?
  • 15. How many clinical trials are studying the ex vivo expansion of cord blood?
  • 16. How many matching and mismatching transplantations using cord blood units are performed on an annual basis?
  • 17. What is the share of cord blood transplants compared to bone marrow and peripheral blood transplants from 2000 to present?
  • 18. What is the likelihood of finding a matching allogeneic cord blood unit by ethnicity?
  • 19. Which are the top ten countries for donating cord blood?
  • 20. What are the diseases targeted by cord blood and tissue-derived MSCs within clinical trials?
  • 21. How many clinical trials are investigating the use of cord blood-derived cells? What is their breakdown by geography, study type, phase, and type of funding?
  • 22. How many clinical trials are exploring the use of cord tissue-derived cells? What is their breakdown by geography, study type, phase, and type of funding?
  • 23. What are the current patent rates and leading jurisdictions for cord blood, cord tissue, and placental patents?
  • 24. Who are the leading inventors, applicants, and owners of these perinatal stem cell patents?
  • 25. How many units are stored by public and private banks worldwide?
  • 26. Who are the leading cord blood banks by region and number of units in storage?
  • 27. What is the global market size for cord blood banking? What is the global market size for cord tissue banking? What is the global market size for the therapeutic applications of cord blood and tissue?

To summarize, this global strategic report presents a comprehensive analysis of the global cord blood and tissue banking market. It includes a detailed market size determination with breakdowns by geography, indication, and type of bank (public versus private), as well as future projections for each market segment through 2030. It reveals the number of cord blood and tissue units stored by public and private cord blood banks worldwide. It also presents the number of cord blood units (CBUs) released by registries across the world for hematopoietic stem cell transplantation (HSCT).

It reveals the identities of companies offering cord blood storage, cord blood processing technologies, cord blood expansion technologies, and cord blood therapeutics on a global basis. It provides coverage of recent M&A transactions, including the consolidation plans executed by the largest cord blood operators worldwide. Given the accelerating complexity and competitive nature of this global market, you don't have the time to do the research. Claim this market report to become immediately informed, without sacrificing hours of unnecessary research.

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.2. Executive Summary
  • 1.3. Introduction

2. CORD BLOOD BANKS: AN OVERVIEW

  • 2.1. Components of a Cord Blood Sample
  • 2.2. Cord Blood Banks
    • 2.2.1. Public Cord Blood Bank
      • 2.2.1.1. Public Cord Blood Banks in the U.S.
      • 2.2.1.2. Public Cord Blood Banks in Major European Countries
      • 2.2.1.3. Economic Model of Public Cord Blood Banks
      • 2.2.1.4. Cost Analysis for Public Cord Blood Banks
      • 2.2.1.5. Relationship between Costs and Release Rates
    • 2.2.2. Private Cord Blood Banks
      • 2.2.2.1. Private Cord Blood Banks in the U.S
      • 2.2.2.2. Top Seven U.S. Private Cord Blood Banks by Size of Inventory
      • 2.2.2.3. Comparison of Top Three U.S. Private Cord Blood Banks
      • 2.2.2.4. Pricing for Processing and Storage of CB in Private Banks
      • 2.2.2.5. Major U.S. Private Cord Blood Banks by their Special Services
      • 2.2.2.6. Key Factors to be Considered by Parents before Choosing a Private Bank
      • 2.2.2.7. World's Top Ten Private Cord Blood Banks by Inventory
      • 2.2.2.8. Special Features of World's Largest Private Cord Blood Banks
      • 2.2.2.9. Cost Analysis for Private Cord Blood Banks
        • 2.2.2.9.1. Economic Model of Private Cord Blood Banks
        • 2.2.2.9.2. Profit Margins of Four Global Private Cord Blood Banks
    • 2.2.3. Hybrid Cord Blood Banks
    • 2.2.4. Cross-over Cord Blood Bank
    • 2.2.5. Community Cord Blood Bank
  • 2.3. Proportion of Public, Private and Hybrid Cord Blood Banks in the U.S.

3. CORD BLOOD BANK ACCREDITATIONS

  • 3.1. American Association of Blood Banks (AABB)
    • 3.1.1. AABB Accreditation Phases and Expectations
  • 3.2. Foundation for the Accreditation of Cellular Therapy (FACT)
    • 3.2.1. FACT Standards
    • 3.2.2. FACT Accreditation Process
  • 3.3. FDA Registration of Cord Blood Banks
    • 3.3.1. FDA Biologics License Application (BLA) for Cord Blood
    • 3.3.2. Investigation New Drug (IND) for Cord Blood
  • 3.4. Human Tissue Authority (HTA) in U.K.
  • 3.5. Therapeutic Goods Act (TGA) in Australia
  • 3.6. International NetCord Foundation

4. PATENT LANDSCAPE OF UMBILICALCORD BLOOD, CORD TISSUE & PLACENTA

  • 4.1. Umbilical Cord Blood Stem Cell Patents
    • 4.1.1. Legal Status of Cord Blood Patents
    • 4.1.2. Umbilical Cord Blood Patent Applications by Year
    • 4.1.3. Umbilical Cord Blood Patent Application by Jurisdiction
    • 4.1.4. Top Ten Umbilical Cord Blood Patent Applicants
    • 4.1.5. Top Ten Inventors of Umbilical Cord Blood Patents
    • 4.1.6. Top Twenty Owners of Umbilical Cord Blood Patents
  • 4.2. Patents on Umbilical Cord Blood-Derived MSCs
    • 4.2.1. Legal Status of UCB-Derived MSC Patents
    • 4.2.2. UCB-Derived MSC Patent Applications by Year
    • 4.2.3. UCB-Derived MSC Patent Application by Jurisdiction
    • 4.2.4. Top Ten UCB-Derived MSC Patent Applicants
    • 4.2.5. Top Ten Inventors of UCB-Derived MSC Patents
    • 4.2.6. Top Twenty Owners of UCB-Derived MSC Patents
  • 4.3. Patents on Cord Tissue
    • 4.3.1. Legal Status of Cord Tissue Patents
    • 4.3.2. Cord Tissue Patent Applications by Year
    • 4.3.3. Cord Tissue Patent Application by Jurisdiction
    • 4.3.4. Top Ten Cord Tissue Patent Applicants
    • 4.3.5. Top Ten Inventors of Cord Tissue Patents
    • 4.3.6. Top Twenty Owners of Cord Tissue Patents
  • 4.4. Patents on Placenta
    • 4.4.1. Leading Placenta-based Patent Applicants
    • 4.4.2. Placental Tissue Patent Applications by Year, 2000-2022
    • 4.4.3. Top Ten Jurisdictions of Placental Tissue Patents
    • 4.4.4. Top Ten Inventors of Placental Tissue Patents
    • 4.4.5. Top Twenty Owners of Placental Tissue Patents
    • 4.4.6. Legal Status of Placental Tissue Patents
  • 4.5. Patents on Cord Blood Expansion
    • 4.5.1. Number of Cord Blood Expansion Patent Applications by Year
    • 4.5.2. Top Ten Jurisdictions of CB Expansion Patents
    • 4.5.3. Legal Status of Cord Blood Expansion Patents
    • 4.5.4. Top Ten Inventors of Cord Blood Expansion Patents
    • 4.5.5. Top 20 Owners of Cord Blood Expansion Patents

5. UMBILICAL CORD BLOOD RESEARCH PUBLICATIONS

  • 5.1. Number of Papers Published on Umbilical Cord Blood
  • 5.2. Scientific Publications on Cord Tissue
  • 5.3. Scientific Publications on Placental Tissue
  • 5.4. Scientific Publications on UCB Cell Expansion

6. CLINICAL TRIAL: CORD BLOOD, CORD TISSUE, PLACENTA AND CB EXPANSION

  • 6.1. Clinical Trials involving Cord Blood Stem Cells
    • 6.1.1. Number of Clinical Trials using Cord Blood Stem Cells by Geography
    • 6.1.2. Number of Cord Blood Clinical Trials by Study Type
    • 6.1.3. Number of Clinical Trials by Phase of Study
    • 6.1.4. Number of Clinical Trials by Funder Type
    • 6.1.5. Diseases Addressed by Currently Recruiting Cord Blood Clinical Trials
    • 6.1.6. Companies Participating in Cord Blood Clinical Trials
  • 6.2. Clinical Trials Using Umbilical Cord Tissue
    • 6.2.1. Number of Clinical Trials using Cord Tissue by Region
    • 6.2.2. Number of Umbilical Cord Tissue Clinical Trials by Phase of Study
    • 6.2.3. Number of Cord Tissue Clinical Trials by Funder Type
    • 6.2.4. Commercial Entities in Umbilical Cord Tissue Clinical Trials
  • 6.3. Clinical Trials using Placental Tissue Stem Cells
    • 6.3.1. Number of Placental Tissue Clinical Trials by Phase of Study
  • 6.4. Clinical Trials of Expanded Cord Blood
    • 6.4.1. Major Participants in Clinical Trials using Expanded Cord Blood Cells

7. CORD BLOOD PROCESSING TECHNOLOGIES: AN OVERVIEW

  • 7.1. The Process of Separation of Cord Blood Stem Cells
    • 7.1.1. PrepaCyte CB
      • 7.1.1.1. Advantages of PrepaCyte-CB
      • 7.1.1.2. Treatment Outcomes with PrepaCyte-CB
    • 7.1.2. Hetastarch (HES)
    • 7.1.3. AutoXpress (AXP)
    • 7.1.4. SEPAX
    • 7.1.5. Plasma Depletion Method (MaxCell Process)
    • 7.1.6. Density Gradient Method
  • 7.2. Comparative Merits of Different Processing Methods
    • 7.2.1. Early Stage HSC Recovery by Technologies
    • 7.2.2. Mid Stage HSC (CD34+/CD133+) Recovery from CB by Technologies
    • 7.2.3. Late Stage Recovery of HSC from Cord Blood by Technologies
    • 7.2.4. HSC (CD45+) Recovery
  • 7.3. Days to Neutrophil Engraftment by Technologies
  • 7.4. Anticoagulants used in Cord Blood Processing
    • 7.4.1. Type of Anticoagulant and Cell Recovery Volume
  • 7.5. Percent Cell Recovery by Sample Size
  • 7.6. TNC Viability by Time Taken for Transport and Type of Anticoagulant
  • 7.7. Cryopreservation of Cord Blood Cells
    • 7.7.1. Ideal Cryoprotectants
  • 7.8. Bioprocessing of Umbilical Cord Tissue (UCT)
  • 7.9. Cord Blood Expansion Technologies
    • 7.9.1. Notch Ligand Delta 1
    • 7.9.2. Co-Culture with MSCs
    • 7.9.3. Copper Chelation
    • 7.9.4. Nicotinamide
    • 7.9.5. StemRegenin 1 (SR1)
    • 7.9.6. UM171
    • 7.9.7. Augmentation of Homing
    • 7.9.8. Prostaglandin E2
    • 7.9.9. Complement 3a (C3a)
    • 7.9.10. Fucosylation

8. CORD BLOOD UNITS AVAILABLE WORLDWIDE: AN OVERVIEW

  • 8.1. Number of Allogeneic CBU Donors and CBUs Available Worldwide
  • 8.2. HLA Typing of Worldwide Unrelated CB Donors and CBUs in 2021
  • 8.3. Unrelated BM, PB and CB Hematopoietic Stem Cell Units Shipped Worldwide
  • 8.4. Global Exchange of Cord HSCs

9. INDICATIONS FOR UMBILICAL CORD BLOOD TRANSPLANTATION

  • 9.1. Beneficial Properties of Cord Blood Stem Cells
    • 9.1.1. Hematopoietic Properties of UCBCs
    • 9.1.2. Immune Properties of UCBCs
    • 9.1.3. Impact of HLA mismatch in UCBT Recipients
  • 9.2. Malignant Indications for UCB Transplantation
  • 9.3. Non-Malignant Diseases Treated by UCB Transplantation
  • 9.4. Diseases being Studied using UCB as Regenerative Medicine

10. CORD BLOOD: AS A TRANSPLANT MEDICINE

  • 10.1. Numbers of CB, BM and PB Stem Cell Transplantations Compared
  • 10.2. Cord Blood Stem Cells Transplantation by Geography, 1999-2021
    • 10.2.1. Indications for Hematopoietic Stem Cell Transplants (HSCTs) in the U.S.
      • 10.2.1.1. Top Five Indications for HCT in the U.S.
      • 10.2.1.2. Trends in Allogeneic HCTs in the U.S., by Recipient Age
      • 10.2.1.3. Trends in the Autologous HCT in the U.S. by Recipient Age
      • 10.2.1.4. HCTs by Cell Source in Adult Patients in the U.S.
      • 10.2.1.5. HCTs by Cell Source in <18 Patients in the U.S.
      • 10.2.1.6. Trends in the Use of Cord Blood HCTs in Adult & <18 Patients in the U.S.
      • 10.2.1.7. Number of Allogeneic CB HCTs in the U.S. by Race
      • 10.2.1.8. Number of HCTs Performed in the U.S. by Cell Source and Donor Type
      • 10.2.1.9. Use of CB Allogeneic HCTs in the U.S. in Recipients Aged <18 Years
      • 10.2.1.10. Use of Allogeneic CB HCTs in the U.S. in Recipients Aged ≥18 Years
    • 10.2.2. Ethnic Background and Cord Blood HLA Matching in the U.S.
    • 10.2.3. Cost of Cord Blood Transplantation
    • 10.2.4. Complications through 1-Year Post HCT

11. CORD BLOOD STEM CELLS IN REGENERATIVE MEDICINE

  • 11.1. Autism
  • 11.2. Cerebral Palsy
  • 11.3. Alzheimer's Disease
  • 11.4. Diabetes
  • 11.5. Heart Diseases
  • 11.6. Multiple Sclerosis
  • 11.7. Stroke

12. MARKET ANALYSIS

  • 12.1. Cord Blood Banking Services Market
    • 12.1.1. Share of Cord Blood Banking Service Market Revenue by Geography
    • 12.1.2. Public vs. Private Cord Blood Banking Service Market
    • 12.1.3. Global Market Share for Cord Blood and Cord Tissue Servicing
  • 12.2. Global Market for Therapeutic Applications of Umbilical Cord Blood & Tissue
    • 12.2.1. Market Share for CB Transplantation and CB for Regenerative Medicine
    • 12.2.2. Percent Share of Cord Blood & Cord Tissue Market by Indication
  • 12.3 Global Market for Umbilical Cord Tissue (UCT)

13. PROFILES OF SELECT CORD BLOOD BANKS & RELATED ORGANIZATIONS

  • 13.1. AllCells
    • 13.1.1. Research Use Only (RUO) Products
      • 13.1.1.1. Mobilized Leukopak
      • 13.1.1.2. Leukopak
      • 13.1.1.3. Bone Marrow
      • 13.1.1.4. Cord Blood
      • 13.1.1.5. Whole Blood
    • 13.1.2. GMP Products
      • 13.1.2.1. Clinical Grade Mobilized Leukopak
      • 13.1.2.2. Clinical Grade Leukopak
      • 13.1.2.3. Clinical Grade Bone Marrow
    • 13.1.3. Isolated Cell Products
      • 13.1.3.1. CD34+ HSPCs
      • 13.1.3.2. T Cells
      • 13.1.3.3. NK Cells
      • 13.1.3.4. Monocytes
      • 13.1.3.5. B Cells
      • 13.1.3.6. PBMCs (MNCs)
  • 13.2. AlphaCord
    • 13.2.1. Prices
  • 13.3. Americord Registry, Inc.
    • 13.3.1. Cord Blood 2.0
    • 13.3.2. Cord Tissue with CryoMax Processing
    • 13.3.3. Placental Tissue with CryoMax processing
  • 13.4. Angiocrine Bioscience
    • 13.4.1. Proprietary E-CEL Platform
  • 13.5. Anja Health Personalized Cord Blood Banking
  • 13.6. Anthony Nolan
    • 13.6.1. Anthony Nolan Grant
  • 13.7. Baylx, Inc.
    • 13.7.1. Product Pipeline
  • 13.8. Be The Match
    • 13.8.1. Hub of Transplant Network
    • 13.8.2. Partners of Be The Match
    • 13.8.3. Allogeneic Cell Sources in Be The Match Registry
    • 13.8.4. Likelihood of a Matched Donor on Be The Match Registry by Ethnicity
    • 13.8.5. Growth of Cord Blood Units on Be The Match Registry
    • 13.8.6. Diversity of CBUs in Be The Match Registry
  • 13.9. Biocell Center
  • 13.10. BioEden
    • 13.10.1. Dental Pulp Cells
    • 13.10.2. Differences between Dental Pulp Cells and Cord Blood Cells
  • 13.11. BioIntegrate, LLC
  • 13.12. Bloodworks Northwest
    • 13.12.1. Products & Services
  • 13.13. California Umbilical Cord Collection Program
    • 13.13.1. Participating Locations
  • 13.14. Carolinas Cord Blood Bank (CCBB)
  • 13.15. Celaid Therapeutics
    • 13.15.1. In Vitro Expansion Technology
    • 13.15.2. Business Model
  • 13.16. Celebration Stem Cell Centre (CSCC)
    • 13.16.1. Products
  • 13.17. Cell Care
  • 13.18. Cellenkos, Inc.
    • 13.18.1. Technology
    • 13.18.2. Cellenkos' Pipeline
  • 13.19. Cells4Life Group LLP
    • 13.19.1. Cellsplus
    • 13.19.2. TotiCyte Processing Technology
    • 13.19.3. Cord Blood Releases from Cells4Life
  • 13.20. CellSave Arabia
    • 13.20.1. Cord Blood Stem Cell Banking Services
    • 13.20.2. Stem Cell Banking Price
  • 13.21. Celularity, Inc.
  • 13.22. Center for International Blood and Marrow Transplant Research (CIBMTR)
  • 13.23. CHOC Blood Bank
  • 13.24. Cleveland Cord Blood Center
    • 13.24.1. Research on Diabetic Retinopathy
    • 13.24.2. Research on Type I Diabetes
    • 13.24.3. Research on Parkinson's disease
    • 13.24.4. Research on Wound Healing
  • 13.25. ClinImmune Cell and Gene Therapy
    • 13.25.1. FDA Licensed Cord Blood
    • 13.25.2. Gene Therapy
    • 13.25.3. Cellular Therapies
  • 13.26. Cord Blood Bank of Arkansas (CBBA)
  • 13.27. Cord Blood Center Group
    • 13.27.1. Cord Blood Units Released form Cord Blood Center Group
  • 13.28. Cord Blood Registry (CBR)
    • 13.28.1. Business Experience
    • 13.28.2. Licensing & Accreditation
    • 13.28.3. Pricing
  • 13.29. Cord for Life
    • 13.29.1. Technology: PremierMax
  • 13.30. CordLife Group, Ltd.
    • 13.30.1. Accreditations & Certifications
    • 13.30.2. Services
    • 13.30.3. Releases from CordLife
    • 13.30.4. Revenue Generation by CordLife Group
  • 13.31. CordVida
  • 13.32. Crioestaminal
    • 13.32.1. Cord Blood Transplantation in Portugal
  • 13.33. Cryo-Cell International, Inc.
    • 13.33.1. Processing Technology
    • 13.33.2. Recovery of Viable CFU by PrepaCyte-CB
    • 13.33.3. Cryo-Cell International's Revenue Generation
    • 13.33.4. Cryo-Cell International's Pricing
  • 13.34. CryoCyte, LLC
  • 13.35. CryoHoldco LATAM
  • 13.36. Cryopoint
  • 13.37. Cryoviva Biotech Pvt., Ltd.
  • 13.38. DKMS gGMBH
    • 13.38.1. Cord Blood Units
    • 13.38.2. Services
    • 13.38.3. DKMS' Donor Typing Profile & Active Donors
  • 13.39. Duke University School of Medicine
    • 13.39.1. Ducord (HPC Cord Blood)
  • 13.40. European Society for Blood and Bone Marrow Transplantation (EBMT)
    • 13.40.1. EBMT Transplant Activity
  • 13.41. Ever Supreme Bio Technology, Co., Ltd.
    • 13.41.1. Allogeneic UMSC01
    • 13.41.2. New Research
  • 13.42. ExCellThera
    • 13.42.1. ECT-001 Cell Therapy
  • 13.43. FamiCord Group
  • 13.44. Fate Therapeutics, Inc.
    • 13.44.1. FT1050 - Stem Cell Modulator
  • 13.45. Future Health
    • 13.45.1. Locations of Laboratories
    • 13.45.2. Business Experience
    • 13.45.3. Collection Kit
    • 13.45.4. Transportation Container
    • 13.45.5. Processing Method
    • 13.45.6. Components Stored
    • 13.45.7. Storage Methods
    • 13.45.8. Licensing & Accreditation
    • 13.45.9. Prices
    • 13.45.10. Additional Services
  • 13.46. Gamida Cell
    • 13.46.1. OMIDUBICELL
  • 13.47. GeneCell
  • 13.48. Global Cord Blood Corporation (GCBC)
    • 13.48.1. GCBC's Revenue Generation
  • 13.49. Glycostem Therapeutics
    • 13.49.1. Science and Technology
    • 13.49.2. oNKord
    • 13.49.3. viveNK
    • 13.49.4. uNiK Production Process
  • 13.50. Hawaii Cord Blood Bank
  • 13.51. HealthBaby
    • 13.51.1. Service Plans
    • 13.51.2. 18-Year Cord Blood (HSCs) Storage Plan
    • 13.51.3. 18-Year CordBasic Umbilical Cord Lining Storage Plan
    • 13.51.4. CellOptima CordPlus Umbilical Cord Lining Storage
  • 13.52. HealthBanksUSA
    • 13.52.1. BioArchive Cryogenic Storage System
    • 13.52.2. AXP Cord Blood Processing
  • 13.53. HEMAFUND
  • 13.54. Hemogenyx Pharmaceuticals
    • 13.54.1. Technology
  • 13.55. IMMUNIQUE
  • 13.56. Insception LifeBank
    • 13.56.1. Cord Blood Releases from Insception LifeBank
    • 13.56.2. Cord Blood Cells Released for Regenerative Medicine from Insception
  • 13.57. JP McCarthy Cord Stem Cell Bank
  • 13.58. Kangstem Biotech, Co., Ltd.
    • 13.58.1. GD11 Brand
    • 13.58.2. Core Technology
  • 13.59. LifebankUSA
  • 13.60. LifeCell International Pvt. Ltd.
  • 13.61. Life Line Stem Cell
  • 13.62. LifeSouth Cord Blood Bank
    • 13.62.1. Accreditation & Hospital Partners
  • 13.63. Magenta Therapeutics
    • 13.63.1. Magenta's Cord Blood-Based Clinical Trial
  • 13.64. Maze Cord Blood
  • 13.65. Medipost, Co., Ltd.
    • 13.65.1. Medipost's Product & Products in Development
      • 13.65.1.1. CARTISTEM
      • 13.65.1.2. PNEUMOSTEM
      • 13.65.1.3. SMUP-IA-01
  • 13.66. Mesoblast, Ltd.
  • 13.67. MD Anderson Cord Blood Bank
  • 13.68. Mesoblast, Ltd.
    • 13.68.1. Mesoblast's UCB-Based Clinical Trial
  • 13.69. MiracleCord, Inc.
    • 13.69.1. AXP II Automated Processing
    • 13.69.2. StemCare Collection Kit
    • 13.69.3. Cost of Cord Blood Banking
  • 13.70. Mononuclear Therapeutics, Ltd.
    • 13.70.1. MonoTx Cord Blood Bank
    • 13.70.2. MonoTx's Pipeline
    • 13.70.3. Products
      • 13.70.3.1. Human Cord Blood Mononuclear Cells (MNCs)
      • 13.70.3.2. Exosome Rich Plasma (ERP)
      • 13.70.3.3. Activated Human Cord Blood Platelet-Depleted-Plasma (aPDP)
  • 13.71. New England Cord Blood Bank, Inc.
    • 13.71.1. Cord Blood Processing
    • 13.71.2. Cord Blood & Tissue Storage
  • 13.72. New York Blood Center
    • 13.72.1. Blood Products & Services
    • 13.72.2. Cell Therapies
    • 13.72.3. Cord Blood
  • 13.73. OrganaBio
    • 13.73.1. OrganaBio's Proprietary Supply Chains
    • 13.73.2. Perenatal Tissues
  • 13.74. PacifiCord
    • 13.74.1. FDA-Approved Sterile Collection Bags
    • 13.74.2. AXP Processing System
    • 13.74.3. BioArchive System
  • 13.75. Plasticell Ltd.
    • 13.75.1. CombiCult Technology
    • 13.75.2. Hematopoietic Stem Cell Expansion
  • 13.76. ReeLabs Pvt. Ltd.
  • 13.77. Restem, LLC
    • 13.77.1. Clinical Trial for COVID-19
    • 13.77.2. Clinical Trial for Muscular Dystrophy
    • 13.77.3. Clinical Trial for Idiopathic Inflammatory Myositis (IIM)
    • 13.77.4. Clinical Trial for Heart Failure
  • 13.78. San Diego Cord Blood Bank
  • 13.79. Saneron CCEL Therapeutics, Inc.
    • 13.79.1. U-CORD-CELL Program
    • 13.79.2. SERT-CELL Program
  • 13.80. SmartCells
  • 13.81. SSM Cardinal Glennon Children's Medical Center
    • 13.81.1. ALLOCORD
  • 13.82. Stembanc, Inc.
    • 13.82.1. Popular Packages from Stembanc
  • 13.83. Stem Cell Cryobank, Inc.
  • 13.84. StemCyte, Inc.
    • 13.84.1. Services
    • 13.84.2. Add On Services
    • 13.84.3. StemCyte in Clinical Trials
    • 13.84.4. StemCyte's Plans & Pricing
  • 13.85. Throne Biotechnologies, Inc.
    • 13.85.1. Effects of CB-SCs in Diabetics
    • 13.85.2. Effects of CB-SCs on Alopecia Areata
  • 13.86. Transcell Biolife
    • 13.86.1. ScellCare
    • 13.86.2. ToothScell
  • 13.87. Upstate Cord Blood Bank
  • 13.88. ViaCord
    • 13.88.1. ViaCord's Complete Services
    • 13.88.2. Cord Blood + Tissue Banking
    • 13.88.3. Newborn Digestive Health
    • 13.88.4. Newborn DNA Guardian
  • 13.89. Versity, Inc.
  • 13.90. Vita 34 AG
    • 13.90.1. Revenue Generation by Vita 34 AG
  • 13.91. Vitalant Clinical Services
    • 13.91.1. Hospital Services
    • 13.91.2. Laboratory Services
    • 13.91.3. Research
  • 13.92. World Marrow Donor Association (WMDA)
    • 13.92.1. WMDA Search & Match Service
  • 13.93. Worldwide Network for Blood & Marrow Transplantation (WBMT)

INDEX OF FIGURES

  • FIGURE 2.1: Parts of an Umbilical Cord
  • FIGURE 2.2: Percent Utilizations of BM-HSCs, PB-HSCs and CB-HSCs in Transplantations
  • FIGURE 2.3: Components of a Cord Blood Sample
  • FIGURE 2.4: Top Seven U.S. Private Cord Blood Banks by Size of Inventory
  • FIGURE 2.5: Cord Blood Revenues for Four Major Private Banks, 2017 to Present
  • FIGURE 2.6: Proportion of Public, Private and Hybrid Cord Blood Banks in the U.S.
  • FIGURE 2.7: % Share of Parents Storing CBUs in Private/Public Banks by Country/Region
  • FIGURE 4.1: Legal Status of Cord Blood Patents
  • FIGURE 4.2: Umbilical Cord Blood Patent Applications by Year, 2000 to Present
  • FIGURE 4.3: Umbilical Cord Blood Patent Application by Jurisdiction
  • FIGURE 4.4: Legal Status of Cord Blood Patents
  • FIGURE 4.5: UCB-Derived MSC Patent Applications by Year, 2000 to Present
  • FIGURE 4.6: UCB-Derived MSC Patent Application by Jurisdiction
  • FIGURE 4.7: Legal Status of Cord Tissue Patents
  • FIGURE 4.8: Umbilical Cord Patent Applications by Year, 2000 to Present
  • FIGURE 4.9: Placental Tissue
  • FIGURE 4.10: Placental Tissue Patent Applications by Year, 2000 to Present
  • FIGURE 4.11: Number of Cord Blood Expansion Patent Applications, 2000 to Present
  • FIGURE 5.1: Number of Published Papers on UCB according to PubMed.gov, 2000 to Present..
  • FIGURE 5.2: Number of Publications on Umbilical Cord Tissue, 2000 to Present
  • FIGURE 5.3: Number of Publications on Placental Tissue
  • FIGURE 5.4: Number of Scientific Publications on UCB Cell Expansion, 2000 to Present
  • FIGURE 6.1: Number of Cord Blood Clinical Trials by Geography
  • FIGURE 6.2: Number of Cord Blood Clinical Trials by Study Type
  • FIGURE 6.3: Number of Cord Blood Clinical Trials by Phase of Study
  • FIGURE 6.4: Number of Cord Blood Clinical Trials by Funder Type
  • FIGURE 6.5: Major Indications Addressed by Currently Recruiting Clinical Trials
  • FIGURE 6.6: Number of Clinical Trials using Cord Tissue by Region/Country
  • FIGURE 6.7: Number of Cord Tissue Clinical Trials by Phase of Study
  • FIGURE 6.8: Number of Cord Blood Clinical Trials by Funder Type
  • FIGURE 7.1: Separation of Buffy Layer
  • FIGURE 7.2: PrepaCyte-CB
  • FIGURE 7.3: Hetastarch (HES)
  • FIGURE 7.4: AutoXpress II
  • FIGURE 7.5: SEPAX 2
  • FIGURE 7.6: Plasma Depletion (PD) Method (MaxCell Process)
  • FIGURE 7.7: Density Gradient Separation of Cord Blood
  • FIGURE 7.8: Early Stage HSC Recovery from Cord Blood by Technologies
  • FIGURE 7.9: Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood by Technologies
  • FIGURE 7.10: Late Stage Recovery of HSC from Cord Blood by Technologies
  • FIGURE 7.11: HSC (CD45+) Recovery Post Process from CB by Technologies
  • FIGURE 7.12: Days to Neutrophil Engraftment by Technologies
  • FIGURE 7.13: Differences in TNC Recovery among Anticoagulants
  • FIGURE 7.14: Type of Anticoagulant and Cell Recovery Volume
  • FIGURE 7.15: Percent Cell Recovery by Sample Size
  • FIGURE 7.16: TNC Viability by Time Taken for Transport
  • FIGURE 7.17: Difference in Recovery of VIABLE TNC after Thawing
  • FIGURE 7.18: CD34+ Cell Count CFU and Cell Apoptosis by Cryoprotectants
  • FIGURE 8.1: HLA Typing of Worldwide Unrelated CB Donors and CBUs
  • FIGURE 8.2: Unrelated BM, PB and CB Hematopoietic Stem Cell Units Shipped Worldwide
  • FIGURE 8.3: Global Exchange of Cord HSCs
  • FIGURE 9.1: Percent Utilization of PB, BM and CB in Transplantations Worldwide
  • FIGURE 10.1: CB, BM and PB Stem Cell Transplantations Compared, 1997-2021
  • FIGURE 10.2: Cord Blood Stem Cells Transplantation by Geography, 1999 to Present
  • FIGURE 10.3: Major Five Indications for HCT in the U.S.
  • FIGURE 10.4: Trends in Allogeneic HCTs in the U.S., by Recipient Age
  • FIGURE 10.5: Trends in the Autologous HCT in the U.S. by Recipient Age
  • FIGURE 10.6: HCTs by Cell Source in Adult Patients in the U.S.
  • FIGURE 10.7: HCTs by Cell Source in <18 Patients in the U.S.
  • FIGURE 10.8: Trends in the Use of CB HCTs in ≥18 & <18 Patients in the U.S.
  • FIGURE 10.9: Number of Allogeneic CB HCTs in the U.S. by Race
  • FIGURE 10.10: Use of CB Allogeneic HCTs in the U.S. in Recipients Aged <18 Years
  • FIGURE 10.11: Use of Allogeneic CB HCTs in the U.S. in Recipients Aged ≥18 Years
  • FIGURE 12.1: Global Cord Blood Banking Service Market, 2022-2030
  • FIGURE 12.2: % Share of Cord Blood Banking Service Market Revenue by Geography
  • FIGURE 12.3: Global Cord Blood Banking Service Market, Public vs. Private
  • FIGURE 12.4: Global CB Banking Service Market Share for Cord Blood and Cord Tissue
  • FIGURE 12.5: Global Market for Therapeutic Applications of Umbilical Cord Blood & Tissue, 2022-2030
  • FIGURE 12.6: Use of Umbilical Cord Blood in Transplantation vs. Regenerative Medicine
  • FIGURE 12.7: Percent Share of Umbilical Cord Blood and Tissue Utilization by Indication
  • FIGURE 13.1: Cell Sources for Allogeneic HCT Facilitated by Be The Match Registry
  • FIGURE 13.2: Likelihood of a Matched Donor on Be The Match Registry by Ethnicity
  • FIGURE 13.3: Growth of CBUs on Be The Match Registry, 2001 to Present
  • FIGURE 13.4: Diversity of CBUs in Be The Match Registry
  • FIGURE 13.5: Funders for CIBMTR in 2022
  • FIGURE 13.6: Sales Revenues and Gross Profits for CordLife, 2014-2021
  • FIGURE 13.7: Cryo-Cell International's Revenue Generation, 2017-2022
  • FIGURE 13.8: GCBC's Revenue Generation, 2015-2022
  • FIGURE 13.9: Revenue Generation by Vita 34 AG, 2014-2021

INDEX OF TABLES

  • TABLE 2.1: An Overview of Public Cord Blood Banks
  • TABLE 2.2: Public Cord Blood Banks in the U.S.
  • TABLE 2.3: Public Cord Blood Banks in Major European Countries
  • TABLE 2.4: International Prices of a Cord Blood Unit (CBU)
  • TABLE 2.5: Prices of CBUs in National Marrow Donor Program (NMDP) Banks in the U.S.
  • TABLE 2.6: An Overview of Private Cord Blood Banks
  • TABLE 2.7: The Leading Private Cord Blood Banks in the U.S.
  • TABLE 2.9: Pricing for Storage in Commercial Cord Blood Banks
  • TABLE 2.10: Leading Private CB Banks by their Inventory Size and Geographic Location
  • TABLE 2.11: World's Largest Private Cord Blood Bank Operators by Inventory
  • TABLE 2.12: Cord Blood Revenues for Four Major Private Banks - 2017 to Present
  • TABLE 2.13: Comparison of Public, Private and Hybrid Cord Blood Banks
  • TABLE 3.1: AABB-Accredited Cord Blood Banks
  • TABLE 3.2: Select FACT-Accredited Cord Blood Banks
  • TABLE 4.1: Umbilical Cord Blood Patent Application by Jurisdiction
  • TABLE 4.2: Top Ten Umbilical Cord Blood Patent Applicants
  • TABLE 4.3: Top Ten Inventors of Umbilical Cord Blood Patents
  • TABLE 4.4: Top Twenty Owners of Umbilical Cord Blood Patents
  • TABLE 4.5: UCB-Derived MSC Patent Applications by Jurisdiction
  • TABLE 4.6: Top Ten UCB-Derived MSC Patent Applicants
  • TABLE 4.7: Top Ten Inventors of UCB-Derived MSC Patents
  • TABLE 4.8: Top Twenty Owners of UCB-Derived MSC Patents
  • TABLE 4.9: Cord Tissue Patent Application by Jurisdiction
  • TABLE 4.10: Top Ten Wharton's Jelly Patent Applicants
  • TABLE 4.11: Top Ten Inventors of Cord Tissue Patents
  • TABLE 4.12: Top Twenty Owners of Cord Tissue Patents
  • TABLE 4.13: Top Ten Applicants of Placental Tissue Patents
  • TABLE 4.14: Top Ten Jurisdictions of Placental Tissue Patents
  • TABLE 4.15: Top Ten Inventors of Placental Tissue Patents
  • TABLE 4.16: Top Twenty Owners of Placental Tissue Patents
  • TABLE 4.17: Legal Status of Placental Tissue Patents
  • TABLE 4.18: Top Ten Jurisdictions of CB Expansion Patents
  • TABLE 4.19: Legal Status of Cord Blood Expansion Patents
  • TABLE 4.20: Top Ten Inventors of Cord Blood Expansion Patents
  • TABLE 4.21: Top Twenty Owners of Placental Tissue Patents
  • TABLE 6.1: Total Number of Umbilical Cord-Related Clinical Studies
  • TABLE 6.2: Number of Cord Blood Clinical Trials by Geography
  • TABLE 6.3: Number of Cord Blood Clinical Trials by Study Type
  • TABLE 6.4: Number of Cord Blood Clinical Trials by Phase of Study
  • TABLE 6.5: Number of Cord Blood Clinical Trials by Funder Type
  • TABLE 6.6: List of Select Companies Participating in Cord Blood Clinical Trials
  • TABLE 6.7: Number of Cord Tissue Clinical Trials by Phase of Study
  • TABLE 6.8: Number of Cord Tissue Clinical Trials by Funder Type
  • TABLE 6.9: Select Commercial Entities in Umbilical Cord Tissue Clinical Trials
  • TABLE 6.10: Number of Placental Tissue Clinical Trials by Phase of Study
  • TABLE 6.11: Major Industry Participants using Expanded Cord Blood in Clinical Trials
  • TABLE 7.1: Advantages of PrepaCyte-CB
  • TABLE 7.2: Treatment Outcomes with PrepaCyte-CB
  • TABLE 7.3: Cord Blood Expansion Approaches in Ongoing Clinical Trials
  • TABLE 8.1: Cord Blood Units Registered with WMDA Registry
  • TABLE 8.2: Number of Unrelated CB Donors and CBUs available Worldwide
  • TABLE 8.3: Unrelated BM, PB and CB Hematopoietic Stem Cell Units Shipped Worldwide
  • TABLE 9.1: Malignant Diseases Treated by UCB Transplantation
  • TABLE 9.2: Non-Malignant Diseases Treated by UCB Transplantation
  • TABLE 9.3: Diseases being studied using UCB as Regenerative Medicine
  • TABLE 10.1: Numbers of CB, BM and PB Stem Cell Transplantations Compared by Year
  • TABLE 10.2: Number of HCTs Performed in the U.S. by Disease as reported to CIBMTR
  • TABLE 10.3: Number of HCTs Performed in the U.S. by Cell Source and Donor Type
  • TABLE 10.4: Comparison of Median Costs during Transplant Admit
  • TABLE 10.5: Complications Post HCT in UCB vs. MRD BM/PBSC vs. MURD BM/PBSC
  • TABLE 11.1: Clinical Trials Evaluating the Effect of Cord Blood Stem Cells on Autism
  • TABLE 11.2: Trials Evaluating the Effect of Cord Blood Stem Cells on Cerebral Palsy
  • TABLE 11.3: Clinical Trials Studying the Effect of CBU on Alzheimer's Disease
  • TABLE 11.4: Clinical Trials Evaluating the Effect of Cord Blood Stem Cells on Diabetes
  • TABLE 11.5: Trials Evaluating the Effect of Cord Blood Stem Cells on Heart Diseases
  • TABLE 11.6: Clinical Trials Evaluating the Effect of UCB on Multiple Sclerosis
  • TABLE 11.7: Clinical Trials Evaluating the Effect of UCB on Stroke
  • TABLE 12.1: Global Cord Blood Banking Service Market, 2022-2030
  • TABLE 12.2: Global Market for Therapeutic Applications of Umbilical Cord Blood & Tissue, 2022-2030
  • TABLE 13.1: Angiocrine's R&D Pipeline
  • TABLE 13.2: Baylx's hUC-MSC-Derived Product Pipeline
  • TABLE 13.3: Growth of Cord Blood Units in Be The Match Registry by Year
  • TABLE 13.4: Diversity of CBUs in Be The Match Registry
  • TABLE 13.5: Cell Care's Pricing for Cord Blood Processing and Storage
  • TABLE 13.6: Cellenkos' Product Pipeline
  • TABLE 13.7: Cord Blood Releases from Cells4Life
  • TABLE 13.8: Celularity's Active Clinical Pipeline
  • TABLE 13.9: Cord Blood Unitts Released from Cord Blood Center Group by Year
  • TABLE 13.10: Cord Blood and Cord Tissue Units Released from CordLife
  • TABLE 13.11: Recovery of Viable CFU by PrepaCyte-CB
  • TABLE 13.12: Cryo-Cell International's Revenue Generation, 2017 to Present
  • TABLE 13.13: Cryo-Cell International's Pricing
  • TABLE 13.14: CryoCyte's Option Plans & Pricing
  • TABLE 13.15: DKMS' Donor Typing Profile & Active Donors
  • TABLE 13.16: Allogeneic and Autologous infusions by Indication Reported by EBMT
  • TABLE 13.17: Cord Blood Banking Cost in GeneCell
  • TABLE 13.18: GCBC's Revenue Generation, 2015 to Present
  • TABLE 13.19: Glycostem's Product Pipeline
  • TABLE 13.20: Insception LifeBank's Pricing
  • TABLE 13.21: Cord Blood Releases from Insception LifeBank for Transplantation
  • TABLE 13.22: Cord Blood Cells Released for Regenerative Medicine from Insception
  • TABLE 13.23: Kangstem's Sponsor Initiated Clinical Trials
  • TABLE 13.24: LifeCell International's Pricing
  • TABLE 13.25: Maze Cord Blood: Banking Cost
  • TABLE 13.26: MiracleCord's Cord Blood Banking Cost
  • TABLE 13.27: MonoTx's Product Pipeline